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Available online 17 March 2016Background: To evaluate in vivo the feasibility and safety of renal sympathetic denervation (RSD) with different
catheters and various radiofrequency protocols.
Methods and results: Twenty-two pigs were included. First 2 pigs were enrolled in a feasibility protocol using one
catheter and power from 5W to 20W. The next 10 pigs underwent RSD with three different catheters and four
different RF-power settings of 5W, 8W, 10W and 12W in oneminute per lesion (Protocol 1). The following 10
(Pigs 13 to 22) underwent RSD with ﬁve types of catheters (including the Symplicity® catheter), powers of 8 W
and 10W and twominutes RF-application (Protocol 2). Angiographic data were obtained at baseline, during and
after RSD. At last, renal arteries were excised and analyzed macroscopically. The ﬁrst pig developed severe renal
stenoses with lesions of 15 to 20 W correlated with macroscopic alterations. The second feasibility pig did not
develop renal stenosis with 5 and 8 W. In Protocol 1 from 60 RF-lesions, we observed 7 stenoses (≥30%). Three
were severe (one of 80% with 10 W and two of 80% with 12 W). In Protocol 2 from 57 lesions we observed
only 1 stenosis of 50% with 8 W with Symplicity® catheter. Severe stenosis was not observed.
Conclusion: In this study, renal sympathetic denervation showed safety using ﬁve types of catheters when
applying RF-energy less than 10 W, within main stems of arteries larger than 3.0 mm diameter and a distance
between lesions of at least 1 time catheter tip length.
© 2016 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Safety of renal denervation1. Introduction
Systemic hypertension represents a major risk factor for cardiovas-
cular morbi-mortality, especially in occidental world [1,2]. Approxi-
mately 90% of these patients do not have a secondary cause and,
despite optimal clinical treatment, blood pressure (BP) levels remain
uncontrolled in about one third [3–7]. Patients taking 3 or more drugs,
including a diuretic, and maintaining high BP levels are classiﬁed in a
group of resistant hypertension. In this setting, sympathetic nervous
system represents a major pathophysiological mechanism for develop-
ment and maintenance of hypertension [8]. Surgical sympathectomy
has been previously attempted however discontinued [9,10]. Recently
a new approach of endovascular renal sympathetic denervation (RSD)
based on radiofrequency (RF) catheter ablation is gaining strength
with convincing results [11,12]. First studies used a ﬁxed protocol
with 4 to 6 focal lesions, in a spiral fashion, using a platinum–iridium(Arrhythmia Department), Rua
0, Brazil.
a).
is an open access article under the C5 F 1.5 mm tip catheter, RF-power up to 8 Watts (W) and 120 s per le-
sion. Reasons for development of such protocol are not completely clear.
Recently, new devices have been developed with particular protocols,
based initially on those trials and have been applied in humans after
few and short time animal testing. The present study sought to evaluate
feasibility and safety of transcatheter RSD in animals testing different
types of unipolar ablation catheters in various RF settings.
2. Methods
We conducted an observational and transversal evaluation of the
feasibility and safety proﬁle of RSD with radiofrequency (RF) catheter
ablation in intact young pigs regarding vascular damage using various
RF-generator settings and different types of ablation catheters. Second-
ary endpoints were the evaluation of macroscopic aspect of RF-lesions
and general signs of traumatic manipulation. The Ethical Committee in
Research fromMedical School of Leipzig University approved the study.
2.1. Study sample
Twenty-two consecutive young healthy pigs underwent percutane-
ous RSD through radiofrequency catheter ablation. The ﬁrst 2 pigsC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
36 B.R. Andrea et al. / IJC Heart & Vasculature 11 (2016) 35–42underwent feasibility protocols. Ten consecutive animals were assigned
to Protocol 1 and a second group of ten animals were assigned to
Protocol 2 (further described).
2.2. Deﬁnitions
Stenosis was deﬁned by an angiographic narrowing of artery lumen
equal or greater than 30% of its original diameter before any manipula-
tion, measured by selective or unselective renal arteries angiography.
Stenoseswere classiﬁed according to the percentage of narrowing com-
pared with the baseline lumen into light (30–50%), moderate (50–70%)
and severe (≥70%). Irregularities were deﬁned by an angiographic
narrowing of artery lumen less than 30% of its original diameter. Trau-
matic manipulation included the presence of any other lesion rather
than the ones placed byRF-catheters on the trajectory to the renal arter-
ies or in their ostia, caused by catheter or sheath manipulation. Careful
analyzes in this regard were conducted after renal arteries and aorta
segment excision.
Macroscopic lesionswere classiﬁed as present or not. In Pigs 1 and 2,
macroscopic analyses were made with triphenyltetrazolium prepara-
tion, which is described further in this article.
2.3. Study protocols
The development of our protocols has been based on current RF-
generator settings in previous trials [11,12], which was ﬁxed at 8 W,
60 °C and 2min time RF-application per lesion. Following these criteria,
programming of RF-generator included different power (W), tempera-
tures (°C) and time in minutes (min). Different types of ablation
catheters have been tested with these RF-settings as follows:
a) Feasibility protocols:
In the ﬁrst 2 pigs, two lesion protocols were deﬁned using the
palladium 6 F 4 mm non-irrigated tip catheter (Biosense Webster
— Diamond Bar, CA, USA). Pig 1 received lesions with 15 and 20 W
and 40 °C in the right renal artery and 10 to 15 W with 40 to 60 °C
in the left one. Each lesion lasted 1 min. Lesions were placed in 3
segments and in opposite sites, meaning 6 lesions in each artery.
After analyzing the results in Pig 1 (see in Results), we applied less
lesions (3 lesions per artery) and less power in Pig 2 with 1 min
RF-application.
After the feasibility-step, the study was conducted with 2 protocols,
each one applied in 10 pigs, respectively.
b) Study protocols:
The ﬁrst protocol was used from Pig 3 to Pig 12 (Protocol 1), and the
second, fromPig 13 to Pig 22 (Protocol 2). Protocol 1 used 3 different
catheters: Palladium 6 F 4 mm non-irrigated tip (Biosense Webster
— Diamond Bar, CA, USA), the gold 6 F 4 mm non-irrigated tip
(Biotronik — Berlin, Germany) and the gold 6 F 3.5 mm irrigated
tip (Biotronik — Berlin, Germany), RF-powers of 5 W, 8 W, 10 W
and 12 W and 1 min each RF-application. In Protocol 2, we used 5
different catheters: The previous 3 in Protocol 1 and added the plat-
inum 5 F 4 mmnon-irrigated tip—Marinr® (Medtronic Inc.—Min-
neapolis, MN, USA) and the platinum–iridium 5 F 2 mm tip
Symplicity® Catheter System™ (Ardian/Medtronic Inc., California,
USA) and RF-powers of 8 W and 10 W. Each lesion lasted 2 min in
accordance to the ﬁxed protocol of Symplicity®. Previously present-
ed, the Symplicity® Catheter System™ provided only a ﬁxed proto-
col of 8 W and 2 min each application [11,12].
c) Lesions placement and contact assurance:
In each pig, two to four lesions were applied per artery, depending
on local anatomy, with an attempt of a 1 time-catheter-tip safe dis-
tance from each lesion in order to avoid RF-lesions in opposite sites
within the same ring-segment, i.e. overlapping lesions. This could
compromise the analysis of each lesion individually. Lesions were
placed mainly at the inferior and superior aspects of the arteries tofacilitate ﬂuoroscopic detection and quantiﬁcation of stenosis in
antero-posterior 0°/0° incidence. This strategy was particularly use-
ful to locate and mark lesions for macroscopic analysis. Contact as-
surance and force were estimated by angiographic analysis and
local impedance changes from a non-contact position.
2.4. Procedure
Pigs were deep anesthetized, intubated and put on mechanical ven-
tilatory support. An experienced veterinarian from the research labora-
tory of the Heart Center Leipzig — Leipzig University supervised the
entire procedure. Standard monitoring with peripheral ECG leads,
blood oxygen saturation, central venous pressure measurement (inter-
nal Jugular vein), central artery pressure (left femoral artery or right ca-
rotid artery) and controlled ventilator parameters. The right femoral
artery was accessed by Seldinger technique with one 11 F in all pigs.
Through this sheath, was introduced a long 8.5 F non-steerable sheath
(for the ﬁrst 5 pigs — SR0) or a 10.5 F steerable sheath (for the last 17
pigs — Agilis®) (both from St. Jude Medical, St. Paul, Minnesota, USA).
The long sheath was advanced until the level of the renal arteries and
their ostia were located by non-selective angiography. The ablation
catheter was than advanced through the long sheath, whichwas placed
nearby the ostia of the arteries, and gently placed inside the right and
left renal arteries, respectively, to perform radiofrequency lesions ac-
cording to the protocols (see Study protocols) (Fig. 1). The RF genera-
tors were the Stockert (Biosense Webster — Diamond Bar, CA, USA)
and Symplicity®™ Generator (Ardian/Medtronic Inc., California, USA).
All pigs received intravenous bolus of 5000 IU heparin after arterial as-
sessment and reinfused to maintain the activated clotting time ≥250,
measured each 30 min. We infused nitrate directly in arteries in some
animals according to the presence of any stenosis after RSD.
2.5. Fluoroscopy analysis
The ﬂuoroscopy intensiﬁer was set to stay at the antero-posterior
projection (AP) 0°/0° in all cases. The ﬁrst contrast injection was in the
Aorta (non-selective) or within each artery ostium as the baseline eval-
uation. After locating the arteries, the long sheath placed nearby the os-
tium of each artery permitted the introduction of ablation catheters.
Angiography control assured the position of the catheter at baseline
(before entering the renal artery), before and after each lesion. At last,
the result was accessed with selective or non-selective angiography
(Fig. 2). Themeasured baseline intraluminal diameter of themain arter-
ies considered the catheter tip as reference in French scale (F) and con-
verted into millimeters (mm). The degree of intraluminal stenosis was
measured by comparison with the same segment before ablation and
quantiﬁed as percent of stenosis (%).
2.6. Anatomy/macroscopy analysis
After ablation and euthanasia, animals had the kidneyswith the arter-
ies and Aorta segment excised. Kidneys were than separated with resec-
tions after the ﬁrst main bifurcation of the renal arteries. The main renal
arteries stems with the Aorta segment received markers (thin stitches)
where each lesion was placed based on ﬂuoroscopic information. In the
ﬁrst 2 pigs from the feasibility protocol, the triphenyltetrazoliumprepara-
tion was used to observe macroscopic lesions (Figs. 2 and 3).
2.7. Statistical analysis
Baseline variables were expressed as mean ± SD. Fisher's exact
test was used to compare differences of lesion formation with the
different catheters in Protocol 2. P value b 0.05 was considered
signiﬁcative.
Fig. 1. Example of renal denervation in Pig 6 (Protocol 1) with the long sheath Agilis® and gold 4 mm non-irrigated tip catheter. Within the right artery (5.8 mm diameter): A — ﬁrst
(distal) lesion with 8 W; B — second (middle) lesion with 5 W; C — third (proximal) lesion with 8 W. Within the left artery (5.6 mm diameter): D — ﬁrst (distal) lesion inside a small
branch (2.1 mm diameter) with 8 W; E — second (middle) lesion with 5 W; F — third (proximal) lesion with 5 W. G — Non-selective angiography before ablation. H — Angiography
after the entire set of lesions showing severe stenosis (80%) in the left inferior small branch after bifurcation (red arrow).
Fig. 2. Renal denervation in feasibility protocol: Pig 1 (A to D— left half of ﬁgure) and Pig 2 (E to H— right half of ﬁgure). Pig 1: A and B show angiographies before denervation from the
right and left arteries, respectively.White arrows are showing the locationswhere lesionswereplaced (power of 10W to20W— see text). C andD show selective angiography of right and
left renal arteries, respectively, after denervation. Red arrows showwhere lesionswere placed. Notice the proximity of each lesion placed at the upper aspect of the right artery, as well as
the greater stenosis degree where the lesions were at opposite sides within the same ring segment. At the left artery is of note that distal lesions were placed very close to the bifurcation
and within the same ring segment. Intravenous local nitrate could not dilate the arteries. Pig 2: E and F show selective angiography before denervation from the right and left arteries,
respectively. White arrows show the locations where the lesions were placed (Power of 5 W and 8 W — see text). Red arrows at G and H show lesions locations after the procedure.
On G there were a slightly irregularity at the distal lesion in the ostium of the ﬁrst inferior branch of right artery (5 W lesion) and on H, just few irregularities within the upper branch
of left artery (8 W lesion).
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Fig. 3.Macroscopic evaluation of Pig 1 (A and B) and Pig 2 (C and D) after denervationwith triphenyltetrazoliumpreparation. OnA the injured tissue is colored inwhitewhich are showed
by red arrows.Notice the severedamage and extension of lesions, especially at the right artery. OnB is noticed a blue coloration at the adventitia (red arrows)meaning transmural necrosis.
Figure C shows the Aorta segment with the renal arteries of Pig 2 before triphenyltetrazolium preparation. Figure D shows the lesions marks in white (red arrows). At this last, even the
distally 5 W lesion could produce tissue damage. Notice no macroscopic damage within the aorta in A or D.
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3.1. Baseline characteristics
From August to November 2011, twenty two consecutive young
healthy pigs underwent percutaneous RSD through radiofrequency
catheter ablation. The ﬁrst 2 pigs (Pig 1 and Pig 2) were included in
the observations and were basically used for procedure feasibility. The
next 10 pigs (Pig 3 to Pig 12) were included in the Protocol 1 and the
last 10 pigs (Pig 13 to Pig 22) underwent Protocol 2. The secondprotocol
was adjusted after analyzing the former, as previously described (see
Study protocols). The pigs weighted between 54 and 75 kg. Comparison
between groups demonstrated signiﬁcantly that animals from Protocol
2 were less weighted (59± 6.3 vs. 69± 2.8 kg— P b 0.05) and renal ar-
teries had smaller diameter (right: 4.75 ± 0.7 vs. 5.8 ± 0.4 mm/left:
5.4 ± 0.6 vs. 6.0 ± 0.6 mm — P b 0.05). In addition, in Protocol 2, theTable 1
Baseline characteristics of samples.
Characteristics Feasibility Pig 1 Feasibility Pig 2 Protocol 1 (me
Length (cm) 125 122 125 ± 1.9
Weight (kg) 68 67 69 ± 2.8
SBP (mm Hg) 100 98 91.5 ± 7.7
DBP (mm Hg) 61 55 51 ± 5.1
Heart rate (bpm) 83 72 84 ± 6.8
CVP (mm Hg) 12 11 12 ± 2.4
SO2 (%) 100 99 99.5 ± 1.2
Anal Temp (°C) 39.4 39.7 39.8 ± 0.4
Aorta diameter (mm) 7.9 12 10.9 ± 1.5
LA main diameter (mm) 3.97 7.77 6 ± 0.6
RA main diameter (mm) 5.25 7 5.8 ± 0.4
LA length (mm) 20.2 12.8 27.2 ± 6.2
RA length (mm) 49.7 31.9 38.8 ± 7.2right arteries had smaller length compared with Protocol 1 (26.4 ±
9.2 vs. 38.8 ± 7.2mm— P b 0.05). Baseline characteristics are described
in Table 1.
3.2. Radiofrequency lesions and end points
A total of 131 lesions were achieved in the 22 pigs: feasibility
protocol — 15 lesions; Protocol 1 — 60 lesions; Protocol 2 — 56 lesions.
These data is summarized in Table 2.
3.3. Feasibility protocol
The catheter usedwas the palladium tip for 1min each RF-lesions. In
Pig 1 we delivered 5 lesions in the right artery with 15W to 20W and 4
lesions in the left artery with 10 W to 15 W alternately. In the right ar-
tery, lesions were placed very close to one another, thus some lesionsan ± SD) Protocol 2 (mean ± SD) Total Value (mean ± SD) P value
125 ± 2.2 124.4 ± 2.1 0.04
59 ± 6.3 65.7 ± 6.1 b0.05
85.5 ± 9.4 89.1 ± 9.5 NS
48.5 ± 2.8 50.7 ± 4.8 NS
86 ± 6.2 82.7 ± 6.6 NS
13 ± 1.6 12.3 ± 2.0 NS
99 ± 3.2 98.5 ± 2.3 NS
39.8 ± 0.5 39.7 ± 0.4 NS
10.5 ± 0.6 10.6 ± 1.2 0.30
5.4 ± 0.6 5.5 ± 0.8 b0.05
4.75 ± 0.7 5.6 ± 0.7 b0.05
25.05 ± 7.0 24.3 ± 6.8 0.19
26.4 ± 9.2 32.4 ± 10.4 b0.05
Table 2
Protocol 1 — Radiofrequency energy delivered during 1 min with the ﬁrst 3 listed catheters and the respective number of stenoses (≥30%) according to power and type of catheter (see
text).
Type of catheter Number of
lesions with
5 W
Number of
stenoses
(%)
Number of
lesions with
8 W
Number of
stenoses
(%)
Number of
lesions with
10 W
Number of
stenoses
(%)
Number of
lesions with
12 W
Number of
stenoses
(%)
Total of
RF-applications
per catheter
Total of
stenoses per
catheter (%)
Gold 4 mm 14 0 (0%) 11 3 (27.3%) 2 0 (0%) 1 0 (0%) 28 3 (10.7%)
Gold irrigated 2 0 (0%) 4 0 (0%) 5 0 (0%) 3 1 (33.3%) 14 1 (7.1%)
Palladium 6 0 (0%) 5 0 (0%) 2 1 (50%) 5 2 (40%) 18 3 (16.7%)
Total RF-applications 22 0 (0%) 20 3 (15%) 9 1 (11.1%) 9 3 (33.3%) 60 7 (11.7%)
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immediately after placement of each lesion independently on power
(15 W or 20 W). In the left artery, the ﬁrst distal lesion was placed
with 10W in a small branch after the ﬁrst bifurcation with 2.50 mm di-
ameter. The next 2 lesions (with 15 W and 10 W) were slightly over-
lapped at the distal segment of the main left stem, which measured
3.97mmdiameter. These 3 places showed severe stenoses. The forth le-
sion (15 W) was placed at the proximal segment of the main stem
(3.97mm) and did not show important stenosis. Angiographic stenoses
and respective macroscopic analyzes are shown in Figs. 2 and 3. At last,
local infusion of nitrate did not show artery dilatation.
According to angiographic results in Pig 1, we deﬁned a different set
of lesions in Pig 2.We applied 4 lesions in the right artery with 5W and
8W alternately and 2 lesions in the left arterywith 8W.We applied RF-
energy in less places compared to Pig 1 in order to avoid overlapping
lesions. We observed only irregularities and no severe macroscopic le-
sions (Figs. 2 and 3). Lesions in the left artery of Pig 2 were placed
after artery bifurcation, within the branches, due to the anatomy of aFig. 4. Samples in Protocol 1 (oneminute RF-time)which presented some degree of angiograph
and A (after)” the procedure. White arrows show where lesions where applied without appare
considered to be stenoses (intraluminal reduction ≥ 30%). Stenosis in Pig 3 in a small branch f
branch with 8 W and gold non-irrigated tip catheter. Stenosis in Pig 9 with gold non-irrigat
after 2 overlapped lesions using 10 W (distal) and 12 W (middle). Two stenoses in Pig 11 usin
the left artery.short main stem of 7.7 mm diameter. The upper and lower branches
measured 3.50 mm and 3.75 mm diameter, respectively, and we did
not observe any stenosis.
3.4. Protocol 1
In this protocol, three catheters were evaluated: the Palladium tip,
gold non-irrigated tip and gold irrigated tip. We evaluated RF-powers
of 5 W, 8 W, 10 W and 12 W with all three catheters. A total of 60
spots of RF applications were performed, each spot for 1 min. This
data is summarized in Table 2.
3.4.1. Analysis of RF-power and stenosis
We observed that RF applications performed with 5 W did not pro-
duce any kind of injury, regardless of the type of catheter used. From
the 20 RF applications performed using 8 W of power, we observed 3
(15%) stenoses. Using the power of 10 W, one stenosis was observed
from 10 RF-applications (11.1%). From 9 RF-applications with 12 Wic damage (Pigs 3, 6, 9, 10 and 11). The legend is represented by: “Pig number— B (before)
nt angiographic damage. Black arrows indicate irregularities. Red arrows indicate lesions
rom right artery with 8 W and gold non-irrigated tip catheter. Stenosis in Pig 6 in a small
ed tip catheter and 8 W. Stenosis in Pig 10 at the left artery with palladium tip catheter
g palladium tip catheter in the right artery with 12 W and gold tip catheter with 12 W in
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in Fig. 4.
3.4.2. Analysis of catheter type and stenoses
Weobserved 3 stenoses out of 28 RF-applicationswith the gold non-
irrigated tip catheter. All three with 8 W power. With gold irrigated tip
catheter we observed 1 stenosis with 12 W from a total of 14 RF-
applications. At last, with the Palladium tip catheter we observed 3
stenoses from 18 RF-applications: One with 10 W and 2 with 12 W.
(Table 2 and Fig. 4 — red arrows).
3.5. Protocol 2
During Protocol 2 we evaluated ﬁve catheters: the Palladium tip,
gold non-irrigated tip, gold irrigated tip, platinum 5 F tip and the
Symplicity® catheter using powers of 8 W and 10 W (except the
Symplicity® system), each for 2 min. Fifty-six ablation spots were per-
formed as shown in Table 3.
3.5.1. Analysis of RF-power, catheters and stenoses
From56RF applicationswe could observe only one stenosiswith the
Symplicity® catheter, which was considered to have 50% lumen reduc-
tion (Fig. 5 — red arrow at Pig 19-A). The power of 10 W has not been
tested using this catheter, since themaximum8W is the valid algorithm
from the respective RF generator (Table 3).
3.5.2. Analysis of mechanical trauma or dissection
During and after all procedures, we did not ﬁnd mechanical trauma
and any artery dissection during and after RSD by angiographic and
macroscopic analyses.
4. Discussion
Based on pathophysiological aspects of resistant essential hyperten-
sion, targeting sympathetic innervation became an attractive aim of
treatment [6–8,13]. In the early 70's, patients with resistant hyperten-
sion were treated surgically with sympathectomy [9,10]. However,
this procedure was discontinued owing to complexity, invasiveness
and high incidence side effects. Intravascular RF-ablation intends to dis-
rupt renal sympathetic innervation less invasively. Themajority of sym-
pathetic nerves are locatedwithin 0.5 to 1.0 depth from the intima layer
of renal arteries [14]. This fact corresponds to the anatomical basis for
RSD. First studies in humans, also using conventional ablation catheters,
have proved safety and positive reproducible clinical results [11,12,
15–18]. Moreover some studies suggest additional clinical beneﬁts
[15,16] and a presumable positive cost-effectiveness [17] with a safe
proﬁle. However, no experimental data clearly supports the apparent
choice of ablation protocols applied in clinical trials. To our knowledge,
this is the ﬁrst study in vivo testing different RF-protocols and various
catheters on feasibility and safety of RSD procedure.
In the present study, we have found very important stenoses with
great RF-power delivered (15–20W) in Pig 1 using a palladium tip con-
ventional ablation catheter. The ﬁrst distal lesion placed within left ar-
tery in Pig 1 was in a small branch after the ﬁrst bifurcation (2.50 mm
diameter), and showed stenotic lesion with less power (10 W). The 2°Table 3
Protocol 2 — Radiofrequency energy delivered during 2 min with all 5 catheters and the respe
Type of catheter tip
according to power
8 W Number of lesions (%) 10 W
Gold 4 mm 5 0 (0%) 5
Gold irrigated 6 0 (0%) 5
Palladium 6 0 (0%) 6
Symplicity®/Ardian 12 1 (%) X
Platinum 5 0 (0%) 6
Total of lesions according to power 34 1 (%) 22and 3° stenotic lesions, with 15 W and 10 W respectively, overlapped
each other at the distal segment of the main left stem, which measured
3.97 mm diameter. The 4° lesion (15W) at the proximal segment of the
main stem (3.97 mm) did not show important stenosis. Therefore we
observed that was unsafe to apply lesions with RF-power equal or
higher than 15 W, within small artery branches (≤2.50 mm) and in a
close distance between spots (overlapping lesions).
In Protocol 1 we observed 7 stenoses from 60 RF-applications. Inter-
estingly, three of them occurred with 8 W and with the gold non-
irrigated tip catheter. Two of them occurred in an artery branch smaller
than 3.0 mm diameter and one within a main stem graded as 30%
(Fig. 4). The three severe stenoses occurred with 8 W (small branch of
2.64 mm from left artery— Fig. 4), 10W and 12 W (overlapped lesions
in Pig 10 — Fig. 4). In Protocol 2 we did not observe severe stenosis ap-
plying 8 W and 10W, except one stenosis of 50% with the Symplicity®
catheterwithin the arterymain stem of 5.4mmdiameter (Fig. 5). In this
protocol, we applied lesions only within main stems.
Interestingly, comparing animals from Protocols 1 and 2, we ob-
served that the second group was composed from smaller samples
and with narrower arteries. This feature, however, did not interfere in
overall result.
Other studies in animal models showed that local changes in endo-
thelial monolayer led to thrombus formation even after 6 months
follow-up [19,20]. As shown previously by optical coherence tomogra-
phy from renal arteries, most patients who underwent RSD with non-
irrigated technology presented acute vascular injury after the proce-
dure. These alterations were mainly edema, thrombus and vasospasms
[21]. This ﬁrst study observed a trend towards the intraluminal throm-
bus formation, i.e. in 89% of the cases using the EnligHTN™ system
(catheter-basket ablation system) and in 53% with the Simplicity
(P = 0.07). A signiﬁcantly greater thrombus load per renal artery was
observed after RSD with the EnligHTN™ system compared with the
Simplicity system (4.6 ± 3.1 vs. 1.5 ± 1.8, P = 0.006) [21]. In our
studywe did not observed any thrombus formation during angiograph-
ic or macroscopic analyses.
Some groups used conventional RF-ablation catheters for RSD with
varied results, however showing safety with particular protocols [18,
22–24]. This experimental study showed safety with either convention-
al RF-catheters or the Symplicity® catheter, in a stepwise testing ap-
proach of the different catheters and RF-settings. The safety was
addressed when ablation was attempted with a RF-power less than
10 W, in artery segments above 3.0 mm diameter and a distance be-
tween lesions at least 1 time the catheter tip length.
In addition, using a 8.5 F non-steerable and a 10.5 F steerable sheath,
we did not observe any mechanical trauma or dissection. This experi-
ence was also recently published in humans [25].
4.1. Limitations
Our study evaluated acute effects of RSD in animal samples with
similar anatomy than human and tested different catheter types and
RF-settings. One limitation includes the small sample number to ob-
serve different variables. We did not conduct a study with chronic ob-
servations, regarding ethical issues in animal studies. In this study we
did not conduct histological evaluation, thus it was not possible toctive number of angiographic lesions (stenosis ≥ 30%) according to power (see text).
Number of lesions (%) Total of lesions according to
catheter
Total of lesions caused
according to catheter
0 (0%) 10 0 (0%)
0 (0%) 11 0 (0%)
0 (0%) 12 0 (0%)
X 12 1 (%)
0 (0%) 11 0 (0%)
0 (0%) 56 1 (%)
Fig. 5. All pigs in Protocol 2 (two-minute RF-time). The legend is represented by: “Pig number — B (before) and A (after)” the procedure. White arrows show the placement of lesions
without angiographic damages. Black arrows indicate lesionswith irregularities after ablation. The red arrow in Pig 19 shows stenotic lesion considered 50%with the Symplicity® catheter.
41B.R. Andrea et al. / IJC Heart & Vasculature 11 (2016) 35–42deﬁne the accomplishment of transmural lesion. Nevertheless themain
endpoint was safety from occurrence of stenosis or macroscopic lesions
after necropsy.
Protocol 1 included more different power settings to test in a small
sample of animals, which could have led to a non-uniform distribution
of RF-lesion placement.5. Conclusion
Radiofrequency ablation for renal sympathetic denervation is safe
when applied with power less than 10 W, in arteries with a diameter
above 3.0 mm and a distance between lesions at least 1 time the cathe-
ter tip length to avoid overlapping of lesions. Renal arteries denervation
with all tested catheters showed to be safe respecting the conditions
mentioned before.Conﬂict of interests
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